Advertisement
Collaboration › Details
Point Biopharma–Eckert & Ziegler: radiopharmaceuticals, 202309–203309 supply 10y >$100m of nca lutetium-177 to Point Biopharma
Period | 2023-09-25 | |
Partner, 1st | Point Biopharma Global Inc. (Nasdaq: PNT) | |
Group | Eli Lilly (Group) | |
Partner, 2nd | Eckert & Ziegler AG | |
Today | Eckert & Ziegler Strahlen- und Medizintechnik AG | |
Group | Eckert & Ziegler (Group) | |
Product | lutetium-177 (medical isotope) | |
Product 2 | RADIOPHARMACEUTICAL (RPT) | |
Eckert & Ziegler AG. (9/25/23). "Press Release: Eckert & Ziegler Signs Strategically Important Agreement for the Supply of Lutetium-177 with POINT Biopharma". Berlin.
Insider information pursuant to Article 17 MAR
Eckert & Ziegler AG (ISIN DE0005659700, SDAX) today signed an agreement with POINT Biopharma Global Inc. ("POINT", NASDAQ: PNT) for the supply of carrier-free lutetium-177 (n.c.a.177Lu). The agreement has a term of ten years with a total sales volume of more than € 100 million.
The lutetium-177 supply is conditional to successful validation of Eckert & Ziegler-produced lutetium-177 with the intended compounds. POINT’s pipeline has multiple lutetium-177-based clinical candidates including one candidate for the treatment of metastatic castration-resistant prostate cancer. The agreement’s projected sales volume is based on the successful regulatory approval of a lutetium-177-based clinical candidate in the future.
To expand its manufacturing capacities, Eckert & Ziegler plans to invest around € 10 million in its own site in Wilmington, MA. Eckert & Ziegler is thus positioning itself as an important supplier of lutetium-177 in the rapidly growing radioligand therapy market.
The strategically significant agreement is expected to start contributing revenues in 2023 and generate substantial earnings if POINT's clinical candidates receive regulatory approval.
The lutetium-177 supply agreement follows a previously signed actinium-225 supply agreement between Eckert & Ziegler and POINT, announced on April 4, 2023.
Contact:
Eckert & Ziegler AG, Karolin Riehle, Investor Relations
Robert-Rössle-Str. 10, 13125 Berlin, Germany
Tel.: +49 (0) 30 / 94 10 84-138, karolin.riehle@ezag.de, www.ezag.com
End of Inside Information
Record changed: 2023-11-12 |
Advertisement
More documents for Eli Lilly (Group)
- [1] Eli Lilly and Company. (12/27/23). "Press Release: Lilly Completes Acquisition of Point Biopharma". Indianapolis, IN....
- [2] Eli Lilly and Company. (11/17/23). "Press Release: Lilly to Expand Injectable Manufacturing Capacity with Planned $2.5 Billion Site in Germany". Indianapolis, IN....
- [3] Eli Lilly and Company. (11/17/23). "Press Release: Lilly Extends Tender Offer to Acquire Point Biopharma to Dec. 1, 2023". Indianapolis, IN....
- [4] Mablink Bioscience SAS. (10/18/23). "Press Release: Mablink Bioscience Enters an Agreement to be Acquired by Lilly". Lyon....
- [5] Eli Lilly and Company. (10/3/23). "Press Release: Lilly to Acquire Point Biopharma to Expand Oncology Capabilities into Next-Generation Radioligand Therapies". Indianapolis, IN....
- [6] Eckert & Ziegler AG. (9/25/23). "Press Release: Eckert & Ziegler Signs Strategically Important Agreement for the Supply of Lutetium-177 with POINT Biopharma". Berlin....
- [7] ITM Isotope Technologies Munich SE. (7/31/23). "Press Release: ITM and Point Biopharma Expand Global Supply Agreement for n.c.a. Lutetium-177". Garching & Indianapolis, IN....
- [8] Heidelberg Pharma AG. (6/29/23). "Press Release: Heidelberg Pharma Sells Minority Shareholding in Emergence Therapeutics (ad hoc announcement)". Ladenburg....
- [9] Eckert & Ziegler AG. (4/4/23). "Press Release: Eckert & Ziegler to Supply Point Biopharma with Actinium-225". Berlin & Indianapolis, IN....
- [10] Roche. (3/22/23). "Press Release: Roche Announces Collaboration with Lilly to Enhance Early Diagnosis of Alzheimer's Disease". Basel....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Advertisement
» top